Table 4_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Data Sheet 1_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.doc by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Table 2_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Table 7_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Table 1_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Table 3_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Data Sheet 2_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.docx by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Table 6_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Table 5_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Data Sheet 1_The impact of climate risks on green technology innovation: an empirical study based on panel data of 269 cities in China.zip by Yangyulong Wu (19867245)

“…First, the two components of climate risks—physical risks and transition risks—significantly hinder green technology innovation. Second, physical risks suppress green technology innovation by reducing market potential, while transition risks do so by decreasing foreign direct investment. …”

Supplementary Material for: Incorporating ALBI Grade with Geriatric Nutritional Risk Index Enhances Hepatocellular Carcinoma Risk Stratification by Nam H. (17688795)

“…Multivariate analysis revealed that a combination of favorable ALBI grade and high GNRI score was independently associated with decreased mortality risk. …”

Supplementary Material for: Effect of endobronchial valve treatment on skeletal muscles, fatigue, and sleep in severe emphysema patients by figshare admin karger (2628495)

“…Intercostal thickening fraction did not change following treatment. Fatigue decreased significantly, reducing severe fatigue prevalence from 70% to 25%. …”

Data_Sheet_10_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.PDF by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Data_Sheet_2_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.PDF by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Data_Sheet_14_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.PDF by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Image_1_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.JPEG by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Raw Data by Kevin Gries (21956942)

“…These findings indicate that a single day of reduced physical activity can elicit modest but significant changes in the metabolic and transcriptomic exercise response. …”

Data_Sheet_12_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.PDF by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Table_1_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.DOC by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Combating Chemoresistance in Breast Cancer: Exploring Tumor Microenvironment, Combination Therapies, and Drug Repurposing Strategies by Shazia Sofi (17764488)

“…Chemoresistance in cancer can arise from a variety of molecular mechanisms, including active drug expulsion (drug efflux), decreased drug uptake, enhanced DNA repair mechanisms, the ability of cancer cells to evade programmed cell death (apoptosis), the diversity in the population of cancer cells within a tumor (tumor heterogeneity), and significant alterations in the tumor microenvironment (TME), where interactions between cancer cells, cancer-associated fibroblasts, immune cells, and the extracellular matrix contribute to a supportive environment that allows tumors to survive treatment and escape therapy. …”